Previous Close | 0.3 |
1-Year Change | -91.8% |
6-Months Change | -69.39% |
3-Months Change | -55.88% |
Moving Avg (50d) | 0.4707 |
Moving Avg (200d) | 0.9013 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 32.1M |
Beta (3-Years) | 1.82 |
Revenue Growth (ttm) | 322.6% |
Net Profit Margin (ttm) | -216.89% |
Return On Assets (ttm) | -7.68% |
EPS (ttm) | -0.08 |
PE Ratio (ttm) | -3.75 |
Dividend Yield | % |
Asset Description: | bluebird bio, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Strong sell |
Forecast Date: | 2024-11-15 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.357 | 0.367 | 0.374 | 0.385 | 0.402 | 0.42 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |